Log In
BCIQ
Print this Print this
 

TPIV 110

  Manage Alerts
Collapse Summary General Information
Company TapImmune Inc.
DescriptionPeptide vaccine using epidermal growth factor receptor 2 (EGFR2; HER2; ErbB2; neu) class I antigens
Molecular Target Epidermal growth factor receptor 2 (HER2) (EGFR2) (ErbB2) (neu)
Mechanism of Action 
Therapeutic Modality 
Latest Stage of DevelopmentPhase I
Standard IndicationBreast cancer
Indication DetailsTreat HER2-positive breast cancer
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today